Related Experiment Videos
Chemotherapy of hormonally unresponsive prostatic carcinoma
Abstract:
The national Prostatic Cancer Project has evaluated single and combination chemotherapeutic agents for the treatment of patients with advanced prostatic cancer that has been unresponsive to hormonal therapy. Although regression rates have been modest, a number of drugs have shown some efficacy and are now undergoing testing in combination. Current trials of the LH-RH agonists and the antiandrogen flutamide are in progress. These trials have demonstrated a role for chemotherapy in the treatment of the patient who has failed hormonal therapy.
Insights
Chemotherapy shows promise for advanced prostate cancer unresponsive to hormone therapy. Ongoing trials combine agents like LH-RH agonists and flutamide, demonstrating chemotherapy
Area of Science:
- Oncology
- Urology
- Pharmacology
Background:
- Advanced prostate cancer often becomes resistant to hormonal therapy.
- Hormone-refractory prostate cancer presents a significant treatment challenge.
Purpose of the Study:
- To evaluate single and combination chemotherapeutic agents for advanced prostate cancer.
- To determine the efficacy of chemotherapy in patients who have failed hormonal therapy.
Main Methods:
- The national Prostatic Cancer Project conducted trials of various chemotherapeutic agents.
- Current investigations involve luteinizing hormone-releasing hormone (LH-RH) agonists and flutamide in combination therapy.
Main Results:
- Modest regression rates were observed with single chemotherapeutic agents.
- Several drugs demonstrated efficacy, leading to combination therapy trials.
- Ongoing trials with LH-RH agonists and flutamide are in progress.
Conclusions:
- Chemotherapy has a demonstrated role in treating advanced prostate cancer.
- Chemotherapy is a viable option for patients with hormone-refractory prostate cancer.
- Combination chemotherapy strategies are being actively investigated.